4//SEC Filing
Alam Kamran 4
Accession 0001209191-23-007396
CIK 0001806310other
Filed
Feb 5, 7:00 PM ET
Accepted
Feb 6, 9:12 PM ET
Size
10.6 KB
Accession
0001209191-23-007396
Insider Transaction Report
Form 4
Alam Kamran
CHIEF FINANCIAL OFFICER
Transactions
- Award
Common Stock
2023-02-02+18,691→ 284,812 total - Award
Employee Stock Option (right to buy)
2023-02-02+37,384→ 37,384 totalExercise: $1.18Exp: 2033-02-02→ Common Stock (37,384 underlying) - Award
Employee Stock Option (right to buy)
2023-02-02+149,900→ 149,900 totalExercise: $1.18Exp: 2033-02-02→ Common Stock (149,900 underlying)
Footnotes (4)
- [F1]Represents a restricted stock unit ("RSU") award. 12,461 RSUs shall vest 25% on each of February 2, 2024, February 2, 2025, February 2, 2026 and February 2, 2027. The remaining RSUs, not subject to time vesting, shall vest upon the achievement of the closing price of the Issuer's common stock on The Nasdaq Stock Market, LLC of at least $4.00 per share on or before December 31, 2023. All vesting is subject to the Reporting Person's continuous service through each applicable vesting date.
- [F2]Each RSU represents a contingent right to receive one share the Issuer's common stock.
- [F3]24,923 shares underlying the option shall vest 25% of the total number of shares underlying the option shall vest and become exercisable on February 2, 2024 and the remainder shall vest and become exercisable in 36 equal monthly installments thereafter. The remaining shares underlying the option, not subject to time vesting, shall vest upon the achievement of the closing price of the Issuer's common stock on The Nasdaq Stock Market, LLC of at least $4.00 per share on or before December 31, 2023. All vesting is subject to the Reporting Person's continuous service through each applicable vesting date.
- [F4]25% of the total number of shares underlying the option shall vest and become exercisable on February 2, 2024 and the remainder shall vest and become exercisable in 36 equal monthly installments thereafter, subject to the Reporting Person's continuous service through each applicable vesting date.
Documents
Issuer
Taysha Gene Therapies, Inc.
CIK 0001806310
Entity typeother
Related Parties
1- filerCIK 0001793412
Filing Metadata
- Form type
- 4
- Filed
- Feb 5, 7:00 PM ET
- Accepted
- Feb 6, 9:12 PM ET
- Size
- 10.6 KB